Ursodeoxycholic Acid

1.Role: long-term use of this drug can increase the secretion of bile acid, and the change of bile composition, reduce the cholesterol in bile and cholesterol ester, is conducive to the cholesterol gallstones gradually dissolve, should not be used for surgical treatment of cholesterol stone.

2.①Cholagogic: every time 50 mg, 150 mg per day.
② Dissolve gallstones: 450 ~ 600 mg daily (8 ~ 10 mg/kg), points 2 times in the morning and evening.After the gallstone removal, oral 50 mg per night, in order to prevent recurrence.
③Hepatomegaly, chronic hepatitis: 8 ~ 13 mg/kg per day, treatment for 6 ~ 24 months.
④ Bile reflux gastritis: 1000 mg per day, 2 times.

3.Adverse reactions: ①The gastrointestinal tract mainly diarrhea, incidence of about 2%.Occasional constipation, stomach pain, pancreatitis, etc.
② The hepatotoxicity of liver toxicity is not obvious.
③The respiratory system data reported abroad, can appear bronchitis, cough, pharyngitis and other respiratory adverse
④The central nervous system Occasional headache, dizziness, etc.
⑤ Skin can appear itching, hair loss, etc.
⑥6. Musculoskeletal There will be joint pain, arthritis, back pain and muscle pain, etc.
⑦Carcinogenic and mutagenic effects Animal studies did not find this drug and mutation, microscope, found no liver cells incubated with this drug there are changes in the structure.Experiments on animals (mice and rats).

4.Note: 1. The contraindications to (1) the severe liver function impairment.Biliary tract
(2) is completely blocked.
(3) allergic to bile acid (foreign).
2. Careful Pregnant women and nursing mothers.
3. The influence of drugs for children The efficacy and safety of children to use this drug is not yet clear, not approved for childre
4. The influence of drugs on pregnancy The FDA this drug is divided into pregnancy risk level for class B.
5. The influence of drugs on inspection value or diagnosis Cholelith disease patients using this drug, blood fat no special change, long-term use of this drug can increase the number of peripheral blood platelet.
6. Before and after medication and drug should check or monitoring
(1) should be at the beginning of treatment, 1 month and 3 months after treatment to check liver enzyme indicators (including alanine aminotransferase and aspartate aminotransferase), after review once every six months.
(2) treatment 1 years should do 1 B ultrasonic examination every six months.
(3) the primary biliary cirrhosis also should pay attention to the total bilirubin, alkaline phosphatase and immunoglobulin IgM monitoring.